Tremelimumab is a monoclonal antibody approved for HCC and NSCLC, used with durvalumab and chemotherapy for unresectable cases.382 Tremelimumab is indicated as a first-line treatment for metastatic NSCLC in patients who do not have sensitizing EGFR mutations or ALK-positive mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.